Health Sciences

A new cancer drug, thanks to a new approach

Researchers in the Abramson Cancer Center helped bring new hope to patients with multiple myeloma with a drug that targets the command center of a cancer cell.

Penn Today Staff

Five questions with Kevin Mahoney

Kevin B. Mahoney, a 23-year veteran of Penn Medicine, became CEO of the University of Pennsylvania Health System on July 1. In a Q&A, Mahoney shares his expertise and inspiration on Penn Medicine’s strengths, where it can improve, and a little insight into his downtime.

Penn Today Staff



In the News


Forbes

Eye drops proven to reverse vision loss in clinical trial

Eve Higginbotham of the Perelman School of Medicine spoke about some of the shortcomings of eye drops that treat age-related farsightedness. “There’s a question of whether or not people will actually use these drops twice a day in order to see a little better up close,” she said. “I am sure there may be a small segment of the population that may choose to put drops in twice a day, but for the vast majority of individuals, using drops twice a day may be a challenge.”

FULL STORY →



Time

‘I burned all the time.’ Selma Blair discusses her MS diagnosis and hope for effective treatments for chronic diseases

Carl June of the Perelman School of Medicine was noted for his contributions to the development of CAR T cell therapy. “The approaches we’ve learned in cancer may well apply to dementia,” he said. “I think that will be the next wave of research.”

FULL STORY →



KYW Newsradio (Philadelphia)

Using a patient portal could help you work harder for your health

Health System CEO Kevin Mahoney spoke about the health benefits of online patient portals. “An engaged patient is more likely to follow guidelines of when you're supposed to get your preventative health care screenings,” he said.

FULL STORY →



Forbes

FDA: Deliveries of scarce childhood cancer drug due to resume later in October, but shortages may continue for months

Peter Adamson of the Perelman School of Medicine authored a letter proposing a “call to action” to make sure childhood-cancer drug shortages don’t reoccur.

FULL STORY →



Philadelphia Inquirer

Penn’s genital herpes vaccine is a winner in animals. Next up: Testing on humans

Harvey Friedman of the Perelman School of Medicine spoke about his efforts to develop an “urgently needed” genital herpes vaccine. “What we have is close to perfect in animals. No one else has done that,” he said. “The big unknown is whether it will work in humans.”

FULL STORY →